According to the latest filing with the U.S. Securities and Exchange Commission (SEC), the biopharmaceutical company Immunic, Inc. has initiated an equity resale program.

The plan allows selling shareholders to register and resell up to 458.2 million shares of common stock. This stock registration aims to provide liquidity for existing shareholders while expanding the company's participation in the capital markets. If all the shares are resold, it may have a certain impact on the company's equity structure. The market will closely monitor subsequent developments to assess the potential impact on the stock price.